An interventional study of Low-dose CT screening and AI full-lung model interpretation system in Respiratory Tract Neoplasms, Thoracic Neoplasms and Neoplasms by Site, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University — 20 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · The First Affiliated Hospital of Guangzhou Medical University.
Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, this one is the 2nd largest by planned enrollment of the 18 interventional ones that give a count, is one of 6 that started in 2024, is one of 12 with no phase, reaches primary completion later than 1 of the 19 other live ones, and was the 13th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →20 of the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University are open now, in 1 country. Recruiting first, the newest first:
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–80
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 40–74 · Healthy volunteers
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 40 Years to 74 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16,000 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 110 across the 18 interventional studies, 550 across the 8 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The First Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 167 studies on the registry; 69 are open to participants now.
7 of the studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07150416The First Affiliated Hospital of Guangzhou Medical UniversityNebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study | 2026-12-01 |
| NCT06778512The First Affiliated Hospital of Guangzhou Medical UniversityLcProt: Proteomics Longitudinal Cohort Study on Lung Cancer | 2026-12-01 |
| NCT06422637The First Affiliated Hospital of Guangzhou Medical UniversityA Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy | 2026-12-01 |
| NCT06843707The First Affiliated Hospital of Guangzhou Medical UniversityEstablishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics. | 2026-12-31 |
| NCT07303881The First Affiliated Hospital of Guangzhou Medical UniversityGolidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Low-dose CT (LDCT)can detect and treat lung cancer earlier and more quickly, while expanded screening coverage helps reduce the incidence and mortality of respiratory diseases such as lung cancer. This study aims to conduct a single-arm cluster randomized trial of digitally enabled LDCT in Guangzhou to assess its intervention effectiveness and cost-effectiveness.
This study uses a single-arm design to assign community health service centers in two districts of Guangzhou (Liwan and Baiyun) to the intervention group. A historical self-comparison design is employed. The intervention measures utilize a digital empowerment model for lung cancer screening, which includes the following components: ① Digital health platform: Each street and community health center manages resident information through the Lung Health mini-program; ② AI-based full-lung model reading system: Using artificial intelligence technology to assist in interpreting CT images; ③ Low-dose CT screening: Low-dose CT screening is conducted at primary healthcare institutions, and patients with detected lung nodules are referred to hospitals for further examination. The sampling method used is Probability Proportional to Size (PPS), with an expected sample size of 16000. Participants will complete the "Lung Cancer Health Questionnaire" to collect individual-level confounding factors. Screening data will be collected through the "Fei'anxin" mini-program, and diagnostic data will be provided by designated hospitals and the First Affiliated Hospital of Guangzhou Medical University. The primary outcome of the study is the proportion of early-stage lung cancer in the screening population, defined as the number of early-stage lung cancer cases divided by the total number of people screened. An economic evaluation of the lung cancer CT screening will also be conducted.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
This study's planned enrollment of 16,000 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →The First Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 167 studies on the registry; 69 are open to participants now.
Compared within Lung Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Respiratory Tract Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
1.Community Health Service Centers (Cluster Level)
Inclusion Criteria The community health service center must be located within one of the 11 districts of Guangzhou.
The center must manage a population of over 10,000 elderly individuals. The center should be equipped with at least one CT machine and have qualified medical personnel, such as radiologists, radiologic technicians, and nursing staff.
Community health service centers where researchers cannot collect data or conduct follow-up.
Inclusion Criteria Aged 40-75 years. Residing in the community participating in the study for a long time. No known history of lung cancer and has not undergone lung cancer screening in the past three months.
Able to understand and willing to sign the form, and able to participate in long-term follow-up.
Individuals unable to understand the study protocol or who cannot provide informed consent due to cognitive impairments.
Individuals participating in other clinical trials that may affect the results of this study.
Individuals unable to undergo follow-up.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Low-dose CT screening · Device: AI full-lung model interpretation system · Device: Digital Health Platform
Low-dose CT screening is conducted at primary healthcare institutions, and patients with detected lung nodules are referred to hospitals for further examination
Using artificial intelligence technology to assist in the interpretation of CT images
Community health centers and streets in Guangzhou use a program called "Fei Anxin" to manage residents' information in a unified way
The early diagnosis rate of lung cancer
Time frame: Within 1 year after the intervention is implemented
The number of participants in lung cancer screening
Time frame: Within 1 year after the intervention is implemented
Number of individuals with positive screening results
Time frame: Within one year after the intervention is implemented
3-month follow-up rate.
Time frame: Within three months after the intervention is implemented
One-year follow-up rate
Time frame: Within 1 year after the intervention is implemented
Diagnosis rate
Time frame: Within 1 year after the intervention is implemented
False positive rate for nodules
Time frame: Within 1 year after the intervention is implemented
Positive predictive value for nodules
Time frame: Within 1 year after the intervention is implemented
Average time to read CT images
Time frame: Within 1 year after the intervention is implemented
CT screening complications
Time frame: Within 1 year after the intervention is implemented
Complications of diagnostic tests
Time frame: Within 1 year after the intervention is implemented
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 12 months is below that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Guangzhou Medical University →